Claxon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claxon

What is Claxon? Defining its Composition and Type

Property Description
Active ingredient Ceftriaxone sodium
Form Powder for solution for injection
Pharmacological class Third-generation cephalosporin (Antibiotic)
General purpose Elimination of bacterial pathogens
Origin Semisynthetic compound

Claxon is a powerful, prescription-only antimicrobial medicine used to treat systemic bacterial infections. Its active ingredient is Ceftriaxone sodium, a compound classified as a semisynthetic beta-lactam antibiotic. This active substance places Claxon within the third-generation cephalosporin group, which is a key subclass of antibiotics recognized for their enhanced stability and broad spectrum of activity against various bacteria. Ceftriaxone is one of the most widely used antibiotics globally, with its efficacy and long half-life being consistently supported by pharmacological studies published in reputable medical literature.


What is the Pharmaceutical Form of Claxon?

Claxon is not available as a pill or tablet; it is formulated as a sterile powder for solution for injection. It is a single-ingredient product that requires reconstitution with a suitable sterile diluent before being administered by a healthcare professional. This particular dosage form and route of administration—either intravenous (IV) or intramuscular (IM) injection—are necessary to ensure that the medicine is delivered directly and quickly into the systemic circulation. This immediate distribution is essential for achieving the high plasma concentrations needed to effectively fight severe or complicated infections throughout the body, making the injectable form a key differentiating feature of this drug entity.


What is the General Purpose of Ceftriaxone?

The general purpose of the active ingredient Ceftriaxone is to act as a potent bactericidal agent, meaning it actively kills infectious bacteria. It achieves this by selectively disrupting the formation of the bacterial cell wall, a process that is crucial for the pathogen's structure and survival but does not occur in human cells. By interfering with the construction of this protective barrier, Claxon causes the fatal structural breakdown of the bacteria. This highly targeted mechanism of effect allows the medicine to decisively eliminate the causative pathogens, leading to the prompt resolution of general bacterial infections.

What side effects are possible with Claxon?

Possible Side Effects and Safety Information

The official regulatory safety profile for this medicine is structured around serious, rare risks and common, transient reactions.


Serious Adverse Reactions

The medicine carries a Boxed Warning from the U.S. Food and Drug Administration (FDA), its most prominent caution, for the risk of Anaphylaxis. Anaphylaxis is a rare, severe, and potentially fatal allergic reaction that can occur at any time during treatment—including after the first dose or up to years after starting the medicine. Official guidance requires immediate discontinuation of the medicine if symptoms of anaphylaxis are suspected.

Common and Other Adverse Reactions

Adverse reactions observed in clinical studies are classified by frequency. The following are among the key documented reactions across different System-Organ Classes:

Category Frequency Examples (System-Organ Class)
Very Common ge 10% Injection site reactions (erythema, pain, pruritus), Vasodilation, Dyspnea
Common 1% to 10% Chest Pain, Immediate Post-Injection Reaction, Rash, Infection, Weight Gain
Uncommon to Rare Lipoatrophy, Skin Necrosis, Anaphylaxis, Hepatic Injury

Immediate Post-Injection Reaction is a distinct set of symptoms (e.g., flushing, fast heartbeat, chest pain, anxiety) that generally occurs shortly after injection and is transient. Regulatory documents caution that the initial symptoms of this common reaction may overlap with those of the rare but severe Anaphylaxis, requiring careful differentiation.

Lipoatrophy (localized fat tissue loss at the injection site) has been reported and is considered permanent. Hepatic Injury has also been noted, and regulatory caution advises considering discontinuation if signs of liver dysfunction occur.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Ceftriaxone (Claxon) may present with documented gastrointestinal manifestations, including nausea, vomiting, and diarrhoea. Of greater concern are severe neurological adverse reactions, which include signs such as a confused state, myoclonus (muscle twitching), convulsions (seizures), and encephalopathy. These serious Central Nervous System (CNS) effects are typically linked to drug accumulation in the body.

Regulators document the risk of high-dose exposure leading to the formation of ceftriaxone-calcium precipitates. This complication may result in urolithiasis (kidney stones) and potentially post-renal acute renal failure.

Immediate medical attention must be sought when severe neurological symptoms or signs of precipitation-related issues are suspected. Treatment for an overdose is symptomatic and supportive, as official labeling confirms that no specific antidote is known. If encephalopathy is suspected, discontinuation of Claxon should be considered. Furthermore, Ceftriaxone concentrations are not effectively reduced by haemodialysis or peritoneal dialysis. Specific regulatory notes address high-risk populations, identifying elderly patients with severe renal impairment as particularly susceptible to neurological toxicity, necessitating close clinical monitoring.

Therapeutic Uses of Claxon

Claxon is used to support robust therapeutic management against severe systemic bacterial infections, including conditions associated with critical physiological stress like Bacterial Meningitis and Septicemia. It is commonly applied for infections of the lungs (pneumonia), abdomen, urinary tract, bone and joints, and for specific conditions like uncomplicated Gonorrhoea.

The primary benefit for the patient is that the medicine supports the body in addressing the causative pathogen, which assists with stabilizing acute episodes and may assist with maintaining functional stability. It targets the pronounced symptomatic patterns that accompany advanced infection, such as high, sudden fever, chills, and pronounced generalized malaise. By assisting the body in addressing the bacterial source, Claxon supports managing the acute inflammatory state, offering support that helps ease the overall symptom burden.

“This medicine is considered relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.”

It is also applied in specific, high-risk clinical contexts, notably for pre-operative prophylaxis before certain surgeries to support the prevention of surgical site infections.

Quick Fact: Relief for Severe Systemic Symptoms Claxon helps address symptom clusters that may become intense or disruptive, such as fever and systemic distress, during acute bacterial episodes.

Regulatory References

  1. FDA-approved indications for Ceftriaxone

Eligibility and Restrictions for Use

Who Can and Cannot Use Claxon? Official Regulatory Information

Claxon (Ceftriaxone sodium) eligibility is determined by specific population characteristics and underlying conditions, as defined in official regulatory labeling. Use is strictly contraindicated in patients with a known history of hypersensitivity to ceftriaxone, any cephalosporin antibiotic, or any other beta-lactam antibacterial agent (such as penicillins).

Neonatal Restrictions: The medicine is absolutely contraindicated for full-term neonates (up to 28 days of age) who have hyperbilirubinemia (jaundice) or who require concurrent calcium-containing intravenous solutions (including parenteral nutrition). Premature neonates up to a postmenstrual age of 41 weeks are also contraindicated.

General Eligibility: Use is generally permitted for adults and children (from 15 days of age) for labeled indications. Older adults typically require no dosage adjustment if renal and hepatic functions are satisfactory.

Conditional Use: Patients with co-existing severe hepatic and renal impairment must limit the total daily dose. Use is not recommended during breastfeeding as the medicine is excreted in human milk in low concentrations, and during pregnancy, it is permitted only if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Claxon (Ceftriaxone) is defined by strict administrative restrictions and pharmacodynamic considerations, as documented in regulatory labeling. The primary focus is on strict constraints necessary to avoid physical incompatibility.

Contraindicated Combinations and Procedural Restrictions

Co-administration of Claxon and intravenous calcium-containing solutions is formally contraindicated in neonates (≤ 28 days of age) due to the severe, documented risk of precipitation in vital organs. In all age groups, Claxon must not be mixed or simultaneously administered with any calcium-containing intravenous solution via a Y-site; the infusion lines must be thoroughly flushed between sequential administrations in non-neonatal patients. Furthermore, diluents containing calcium must not be used for the reconstitution or further dilution of the product.

Documented Drug-Drug Interactions

Interacting Substance/Class Official Interaction Outcome
Anticoagulants (e.g., Warfarin) May increase the anticoagulant effect, resulting in an increased International Normalized Ratio (INR) and heightened bleeding risk.
Bacteriostatic Antibiotics May result in pharmacodynamic antagonism, potentially reducing Claxon's bactericidal effect.
Oral Contraceptives May decrease the level or effect of the hormones by altering intestinal flora.
Food / Alcohol No known interaction with food is documented; the effect of alcohol is officially noted as unknown.

The official profile emphasizes procedural constraints related to the medicine's physical incompatibility and documented effects on the patient's hemostatic system, rather than common metabolic enzyme interactions.

Mechanism of Action

How Claxon Works: Mechanism of Action

Claxon's function is to directly and selectively influence the blood coagulation cascade through indirect allosteric activation of antithrombin.


Targeted Inhibition of Factor Xa

Claxon primarily works by binding to and activating the naturally occurring protein, antithrombin (AT), which is critical for regulating coagulation. This enhanced AT rapidly and specifically targets and neutralizes Coagulation Factor Xa (FXa), an essential enzyme in the coagulation process. This key interaction curtails the molecular cascade from progressing effectively, thereby significantly limiting the production of thrombin.


Interference with Fibrin Generation

By blocking Factor Xa, and with secondary inhibition of thrombin (Factor IIa) by the activated antithrombin complex, Claxon impedes the final stages of blood coagulation. This interference restricts the conversion of the soluble protein fibrinogen into the insoluble fibrin strands, which are required for clot structure. This system-level modification of the coagulation process is mechanistically observed as a prolonged coagulation time.

Dosage and Administration Information

How to Use Claxon (Diclofenac Sodium Injection) — Administration Guidelines

Claxon injection is for short-term use only, administered according to the instructions for its specific route of administration. Treatment with the injection should not exceed two days.

Administration Details

Guideline Instruction (Intramuscular Use)
Route Deep intragluteal injection (into the upper outer quadrant of the buttock).
Dosing 75 mg once daily (one ampoule). In severe cases, up to two injections daily (150 mg maximum), given into alternate buttocks.
Duration Not to be given for more than 2 days. Continued treatment, if necessary, must be with oral tablets.
Preparation Ready-to-use solution for injection; no dilution or reconstitution is specified for the intramuscular route.
Age Restriction Not suitable for children.

Procedural Steps

To ensure proper administration and minimize local tissue damage, the following steps are followed:

  1. The Claxon solution is injected deep intragluteally into the upper outer quadrant of the buttock.
  2. If a second daily injection is required for severe cases, it is administered into the alternative buttock after an interval of a few hours.
  3. The injection is given slowly and at a steady rate.

This defined procedure ensures the injection is used for acute initial therapy, preventing prolonged use via the intramuscular route.

Recent Clinical Evidence

Research evidence / Overview of Studies for Claxon

The evidence for Claxon (ceftriaxone) comes from decades of clinical studies, primarily Randomized Controlled Trials (RCTs) and comprehensive meta-analyses conducted globally. This research explores whether the medicine was associated with measured outcomes when used for severe, acute bacterial infections. Findings describe patterns observed in the studies, contributing to the broader evidence landscape.


Evidence for Use in Acute and Severe Infections

This section summarizes the core evidence base, primarily consisting of comparative randomized controlled trials and meta-analyses, which examined the use of Claxon for major systemic conditions, focusing on the research aims and the outcomes measured in those studies.

Research on Bacterial Meningitis

Research examined the use of Claxon for conditions characterized by acute or disruptive episodes of bacterial meningitis in patients of various ages. Researchers monitored primary endpoints such as all-cause mortality, the rate of microbiological clearance, and the presence of long-term neurological impairment. The evidence indicates that while outcomes such as mortality were key endpoints, certainty remains low or very low for many findings due to methodological limitations in older trials and variability in outcome measurement.

Research on Community-Acquired Pneumonia (CAP)

Research examined the use of Claxon in hospitalized patients with Community-Acquired Pneumonia (CAP), a condition marked by functional limitations. The evidence base includes RCTs and systematic reviews that compared different antibiotic regimens. Findings indicate patterns related to short-term symptom changes when compared with alternative antibiotic agents, tracking outcomes like 30-day mortality/survival and hospital length of stay (LOS). For patients with severe CAP, studies suggest that higher doses may show patterns related to 30-day mortality compared to lower doses, indicating that subgroup findings are uncertain.


Long-Term Evidence and Follow-up Durations

Research explored responses over defined time intervals, with most clinical trials for Claxon focusing on the acute phase of infection. Follow-up durations were limited, typically lasting only the duration of treatment or up to 30 to 90 days following discharge. However, there is limited information for long-term outcomes regarding the durability of response or any extended impact on physiological function after the acute recovery period for most indications. These areas require ongoing research to establish certainty.

Key Studies & References

  1. Ceftriaxone FDA Label and Prescribing Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Claxon (FAQ)


Q: What is Claxon used for, in simple terms?

Claxon (ceftriaxone) is classified as a powerful, prescription-only antibiotic. According to the official product information, it is used to treat serious bacterial infections, such as certain types of meningitis and severe pneumonia. Because of its nature, a healthcare professional must administer it.


Q: Is it normal to feel a bit dizzy when first starting Claxon?

Regulatory documents list dizziness as a reported adverse reaction for the active ingredient ceftriaxone. Other neurological reactions, including somnolence (drowsiness), have also been reported. Regulatory guidance suggests patients contact a healthcare provider if dizziness is persistent or severe.


Q: Is Claxon safe for people with kidney problems?

Official information indicates that dosage adjustments are generally not necessary for the active ingredient ceftriaxone in patients who have isolated kidney failure. However, official information notes that a dose limitation is specified for patients who have co-existing severe liver and kidney problems, due to how the medicine is processed by the body.


Q: Will Claxon make me feel sleepy or tired?

Regulatory documents note the possibility of neurological adverse reactions, including somnolence (drowsiness) and lethargy (tiredness or lack of energy). Due to this possibility, official product information includes a warning regarding caution when performing tasks that require full mental alertness, such as driving or operating machinery.


Q: What does 'contraindications' mean for Claxon?

The term contraindication is used in official documents to identify specific patient situations where the medicine must not be used because the risks significantly outweigh the benefits. For Claxon, these situations include having a severe allergy to the drug or being a very young baby (neonate) with high levels of bilirubin.


Q: Why are people with liver conditions generally advised against using Claxon?

The medicine is processed and eliminated from the body through both the kidneys and the bile (liver). Official documents note that caution and a maximum daily dose limit are specified for patients who have co-existing severe liver and kidney impairment.


Q: Why is Claxon used for [Disease Claxon treats]?

Claxon’s active ingredient, ceftriaxone, is a third-generation cephalosporin known for being effective against many types of bacteria that cause serious infections. It is often selected for its long elimination half-life, which allows for convenient once-daily dosing.


Q: What should I do if a side effect of Claxon seems severe?

Official guidance states that if signs of a serious reaction, such as a severe allergic reaction (anaphylaxis) or a neurological adverse reaction, occur, treatment must be discontinued immediately. Official guidance describes that appropriate medical support measures are necessary.


Q: What is the evidence supporting the use of Claxon in children?

Safety and effectiveness have been established for the use of ceftriaxone in infants (from 15 days of age) and children for the drug's labeled indications. Regulatory documents include specific dosage guidelines for these younger populations.


Q: How do regulators describe the overall safety profile of Claxon?

Claxon is approved for use in treating serious bacterial infections. Regulators emphasize that it carries a Boxed Warning, the most prominent safety caution, for the risk of fatal ceftriaxone-calcium precipitation in neonates and for the risk of severe allergic reaction (anaphylaxis).


Q: Are there different strengths or doses of Claxon available?

Yes, according to official product information. The active ingredient ceftriaxone is formally available as a powder for injection in multiple strengths, which often include 250 mg, 500 mg, 1 gram, and 2 grams.


Q: What is the shelf life of Claxon?

Regulatory information specifies that the unreconstituted powder must be stored at controlled room temperature and protected from light. The reconstituted solution has limited stability, meaning it must be used within a short, specific time frame (which varies by storage temperature) before being discarded.


Q: Can women who are planning pregnancy use Claxon?

The medicine is assigned Pregnancy Category B by the FDA. Official documents advise that it is intended to be used during pregnancy only if it is clearly needed, suggesting the decision is based on clinical necessity during the period of planning or conception.


Q: Are headaches a commonly reported side effect of Claxon?

Headaches are listed in regulatory documents as a reported adverse reaction for the active ingredient ceftriaxone. Patients are generally advised in official documents to contact a healthcare provider if headaches become bothersome or do not resolve.


Q: Is Claxon a new drug, or has it been around for a while?

The active ingredient, ceftriaxone, is not considered a new drug. It has been used for decades since its initial regulatory approval and continues to be one of the most widely used antibiotics globally due to its established efficacy.


Q: How quickly does Claxon start working?

The bactericidal (bacteria-killing) action of ceftriaxone begins rapidly via the inhibition of bacterial cell-wall synthesis. The medicine achieves its highest concentration in the blood within hours of intramuscular injection.


Q: How long does the effect of Claxon typically last?

The active ingredient ceftriaxone has a long elimination half-life in healthy adults, ranging from approximately 5.8 to 8.7 hours. This long duration is the pharmacological basis that supports its typical once-daily dosing regimen.


Q: What's the difference between Claxon and [Name of Common Competitor Drug]?

Claxon’s active ingredient, ceftriaxone, is a third-generation cephalosporin antibiotic known for its broad spectrum of activity against various bacteria. Its primary differentiating feature is its long half-life, which is a key factor supporting its once-daily use for severe infections.


Q: What happens if I miss a dose of Claxon?

Since Claxon is used for serious infections, it is intended to be administered on a fixed, strict schedule. If a dose is missed, patient guidance advises contacting a healthcare provider or pharmacist immediately for specific instructions.


Q: Is there a generic version of Claxon available?

Yes, regulatory records, such as those kept by the FDA, indicate that a lower-cost generic version of the active ingredient, ceftriaxone sodium, is available and widely used globally.


Q: Does the time of day I take Claxon affect how well it works?

Regulatory documents specify a dosing frequency (e.g., once daily) for the medicine but do not specify a mandatory time of day for administration. The focus is on ensuring the medicine is administered as scheduled by the healthcare professional.


Q: Can Claxon affect my ability to drive or operate machinery?

Official regulatory documents state that the medicine may have an influence on the ability to drive or operate machinery. This is based on the possibility of adverse reactions such as dizziness or somnolence (drowsiness) occurring.


Q: Is Claxon considered a Schedule drug or controlled substance?

No. Regulatory bodies, including the Drug Enforcement Administration (DEA) in the U.S., classify the active ingredient ceftriaxone as not a controlled medication or scheduled substance under the Controlled Substances Act.


Q: How is Claxon processed by the body?

According to the official clinical pharmacology information, the medicine is processed by the body via biliary and renal excretion. Approximately 33% to 67% of a dose is excreted in the urine, and the remainder is secreted in the bile.


Q: How long does Claxon take to leave the body?

The active ingredient ceftriaxone has an elimination half-life that ranges from approximately 5.8 to 8.7 hours in healthy adults. This half-life is the time it takes for half of the dose to be removed from the body.


Q: Do official sources mention Claxon being used for preventing symptoms?

Official documents state that the medicine is indicated for the treatment of infections. However, it is also used for pre-operative prophylaxis, which means preventing surgical site infections before they occur.


Q: What does the patient leaflet say about stopping Claxon?

Patient guidance from official sources strongly emphasizes that the medication is intended to be taken exactly as directed and the full course of therapy completed to prevent the development of resistant bacteria.


Q: What kind of monitoring is recommended while taking Claxon?

Regulatory documents advise that laboratory monitoring may be recommended during treatment. This often includes blood tests like a CBC with differential, as well as tests to check renal (kidney) and hepatic (liver) function.


Q: What are the ingredients besides the main active one in Claxon?

The product contains the main active ingredient, ceftriaxone sodium. Since it requires reconstitution, other ingredients vary by the specific product or diluent used, but they may commonly include substances like sodium and dextrose.

How should Claxon be stored and disposed of?

How to Store and Dispose of Claxon (Ceftriaxone Injection)

The storage and disposal requirements for Ceftriaxone sodium (Claxon) powder for solution for injection are strictly defined by regulatory documents to maintain product integrity.


Storage Requirements

  • The unreconstituted powder must be stored in the original container at Controlled Room Temperature (typically 20 C to 25 C).
  • The medicine must be protected from light and should not be frozen or exposed to temperatures above 30 C.
  • After reconstitution, the solution has limited stability and must be used within the time specified on the label (e.g., up to 10 days refrigerated) before being discarded.
  • Claxon must be kept out of the reach and sight of children.

Disposal Instructions

  • Expired or unused Claxon must be disposed of according to local requirements for unused medicinal products.
  • The product must not be disposed of in wastewater or typical household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Claxon found in:

A-Z Index: